Allarity Therapeutics Files 8-K

Ticker: ALLR · Form: 8-K · Filed: Jun 3, 2025 · CIK: 1860657

Sentiment: neutral

Topics: 8-K, regulatory-filing, financial-statements

Related Tickers: ALLR

TL;DR

ALLR filed an 8-K on June 3rd for events on June 2nd. Check it out.

AI Summary

Allarity Therapeutics, Inc. filed an 8-K on June 3, 2025, reporting other events and financial statements. The filing date for the report is June 2, 2025. The company is incorporated in Delaware and its principal executive offices are located in Tarpon Springs, FL.

Why It Matters

This 8-K filing indicates that Allarity Therapeutics, Inc. is making a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for other events and financial statements, not indicating immediate significant financial distress or major corporate changes.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported in this 8-K filing?

The provided text does not detail the specific 'Other Events' being reported, only that this item is included in the filing.

What is the significance of the 'Financial Statements and Exhibits' being filed?

The filing of 'Financial Statements and Exhibits' suggests that the company is providing updated financial information or supporting documents as required by the SEC.

What is the company's primary business as indicated by its SIC code?

The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to 'Pharmaceutical Preparations'.

When was the company incorporated and where are its principal executive offices located?

The company was incorporated in Delaware and its principal executive offices are located at 123 E Tarpon Ave, Tarpon Springs, FL 34689.

What is the registrant's telephone number?

The registrant's telephone number is (401) 426-4664.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Allarity Therapeutics, Inc. (ALLR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing